Trial reportJournal of substance abuse treatment2022
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes.
Trial report in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.Drug and alcohol dependence · 2025Trial
- Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Trial
- Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.Addiction science & clinical practice · 2023Trial
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
- Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.The American journal of psychiatry · 2026Article
- Prenatal substance use and mental health comorbidities predict continued use.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Article
- Animal models of cocaine use: importance of social context and co-use.Trends in pharmacological sciences · 2025Review
- A Mixed-Methods Study of Motives for Benzodiazepine Misuse Among Adults Receiving Substance Use Disorder Treatment.Substance use & misuse · 2025Article
- Review
- Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.Drug and alcohol dependence · 2023Article
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.Addiction science & clinical practice · 2023Article
- Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.Substance abuse treatment, prevention, and policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectivePolysubstance use may complicate treatment outcomes for individuals who use opioids. This research aimed to examine the prevalence of polysubstance use in an opioid use disorder treatment trial population and polysubstance use's association with opioid relapse and craving.
methodsThis study is a secondary data analysis of individuals with opioid use disorder who received at least one dose of medication (n = 474) as part of a 24-week, multi-site, open label, randomized Clinical Trials Network study (CTN0051, X:BOT) comparing the effectiveness of extended-release naltrexone versus buprenorphine. Models examined pretreatment polysubstance use and polysubstance use during the initial 4 weeks of treatment on outcomes of relapse by week 24 of the treatment trial and opioid craving.
resultsPolysubstance use was generally not associated with treatment outcomes of opioid relapse and craving. Proportion of days of pretreatment sedative use was associated with increased likelihood of opioid relapse (OR: 1.01, 95 % CI: 1.00-1.02). Proportion of days of cocaine use during the initial 4 weeks of treatment was associated with increased likelihood of opioid relapse (OR: 1.05, 95 % CI: 1.01-1.09) but this effect was no longer significant once the potential of confounding by opioid use was considered. Sedative use during initial 4 weeks of treatment was associated with increased opioid craving (b: 0.77, 95 % CI: 0.01-1.52). The study found no other significant relationships.
conclusionsIn the current study population, polysubstance use was only marginally associated with 24-week treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.